258 related articles for article (PubMed ID: 27223068)
1. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
[TBL] [Abstract][Full Text] [Related]
2. Measurements of complement factor H-related protein (BTA-TRAK assay) and nuclear matrix protein (NMP22 assay)--useful diagnostic tools in the diagnosis of urinary bladder cancer?
Mahnert B; Tauber S; Kriegmair M; Nagel D; Holdenrieder S; Hofmann K; Reiter W; Schmeller N; Stieber P
Clin Chem Lab Med; 2003 Jan; 41(1):104-10. PubMed ID: 12636058
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic role of urinary collagens in primary human bladder cancer.
Miyake M; Morizawa Y; Hori S; Tatsumi Y; Onishi S; Owari T; Iida K; Onishi K; Gotoh D; Nakai Y; Anai S; Chihara Y; Torimoto K; Aoki K; Tanaka N; Shimada K; Konishi N; Fujimoto K
Cancer Sci; 2017 Nov; 108(11):2221-2228. PubMed ID: 28837258
[TBL] [Abstract][Full Text] [Related]
4. [Non-invasive urine tests in diagnosis and as prognostic markers for urinary bladder carcinoma. Comparison of the BTAstat and NMP 22 tests with immunocytology using monoclonal antibodies against Lewis X and 486p3/12].
Friedrich MG; Hellstern A; Hautmann SH; Noldus I; Huland H
Urologe A; 2003 Apr; 42(4):523-30. PubMed ID: 12715124
[TBL] [Abstract][Full Text] [Related]
5. Identification and validation of AIB1 and EIF5A2 for noninvasive detection of bladder cancer in urine samples.
Zhou BF; Wei JH; Chen ZH; Dong P; Lai YR; Fang Y; Jiang HM; Lu J; Zhou FJ; Xie D; Luo JH; Chen W
Oncotarget; 2016 Jul; 7(27):41703-41714. PubMed ID: 27203388
[TBL] [Abstract][Full Text] [Related]
6. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic potential in bladder cancer of a panel of tumor markers (calreticulin, gamma -synuclein, and catechol-o-methyltransferase) identified by proteomic analysis.
Iwaki H; Kageyama S; Isono T; Wakabayashi Y; Okada Y; Yoshimura K; Terai A; Arai Y; Iwamura H; Kawakita M; Yoshiki T
Cancer Sci; 2004 Dec; 95(12):955-61. PubMed ID: 15596044
[TBL] [Abstract][Full Text] [Related]
8. The use of urinary nuclear matrix protein 22 (NMP22) as a diagnostic adjunct to urine cytology for monitoring of recurrent bladder cancer--institutional experience and review.
Önal B; Han Ü; Yilmaz S; Köybasioglu F; Altuğ U
Diagn Cytopathol; 2015 Apr; 43(4):307-14. PubMed ID: 25488052
[TBL] [Abstract][Full Text] [Related]
9. HOXA9, PCDH17, POU4F2, and ONECUT2 as a Urinary Biomarker Combination for the Detection of Bladder Cancer in Chinese Patients with Hematuria.
Wu Y; Jiang G; Zhang N; Liu S; Lin X; Perschon C; Zheng SL; Ding Q; Wang X; Na R; Sun J; Xu J
Eur Urol Focus; 2020 Mar; 6(2):284-291. PubMed ID: 30309818
[TBL] [Abstract][Full Text] [Related]
10. Detection of newly diagnosed bladder cancer, bladder cancer recurrence and bladder cancer in patients with hematuria using quantitative rt-PCR of urinary survivin.
Kenney DM; Geschwindt RD; Kary MR; Linic JM; Sardesai NY; Li ZQ
Tumour Biol; 2007; 28(2):57-62. PubMed ID: 17259754
[TBL] [Abstract][Full Text] [Related]
11. Carbonic anhydrase IX as a diagnostic urinary marker for urothelial bladder cancer.
de Martino M; Lucca I; Mbeutcha A; Wiener HG; Haitel A; Susani M; Shariat SF; Klatte T
Eur Urol; 2015 Oct; 68(4):552-4. PubMed ID: 26138037
[TBL] [Abstract][Full Text] [Related]
12. Highly sensitive and specific novel biomarkers for the diagnosis of transitional bladder carcinoma.
Kumar P; Nandi S; Tan TZ; Ler SG; Chia KS; Lim WY; Bütow Z; Vordos D; De la Taille A; Al-Haddawi M; Raida M; Beyer B; Ricci E; Colombel M; Chong TW; Chiong E; Soo R; Park MK; Ha HK; Gunaratne J; Thiery JP
Oncotarget; 2015 May; 6(15):13539-49. PubMed ID: 25915536
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of urine CYFRA 21-1 for the detection of primary and recurrent bladder carcinoma.
Nisman B; Barak V; Shapiro A; Golijanin D; Peretz T; Pode D
Cancer; 2002 Jun; 94(11):2914-22. PubMed ID: 12115379
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic value of combined IQGAP3/BMP4 and IQGAP3/FAM107A expression ratios in urinary cell-free DNA for discriminating bladder cancer from hematuria.
Xu Y; Kim YH; Jeong P; Piao XM; Byun YJ; Kang HW; Kim WT; Lee JY; Kim IY; Moon SK; Choi YH; Yun SJ; Kim WJ
Urol Oncol; 2019 Jan; 37(1):86-96. PubMed ID: 30446454
[TBL] [Abstract][Full Text] [Related]
15. Panel of Urinary Diagnostic Markers for Non-Invasive Detection of Primary and Recurrent Urothelial Urinary Bladder Carcinoma.
Soukup V; Kalousová M; Capoun O; Sobotka R; Breyl Z; Pešl M; Zima T; Hanuš T
Urol Int; 2015; 95(1):56-64. PubMed ID: 25662337
[TBL] [Abstract][Full Text] [Related]
16. [Tumor markers for bladder cancer: up-to-date study by the Kiel Tumor Bank].
Hautmann S; Eggers J; Meyhoff H; Melchior D; Munk A; Hamann M; Naumann M; Braun PM; Jünemann KP
Urologe A; 2007 Nov; 46(11):1508-13. PubMed ID: 17932643
[TBL] [Abstract][Full Text] [Related]
17. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
[TBL] [Abstract][Full Text] [Related]
18. [Bladder cancer screening with urine-based tumour markers - occupational medical experience].
Nasterlack M; Feil G; Leng G; Pesch B; Huber S; Sievert KD; Johnen G; Taeger D; Mayer T; Kluckert M; Brüning T; Stenzl A
Aktuelle Urol; 2011 Mar; 42(2):128-34. PubMed ID: 21437837
[TBL] [Abstract][Full Text] [Related]
19. A multi-analyte assay for the non-invasive detection of bladder cancer.
Goodison S; Chang M; Dai Y; Urquidi V; Rosser CJ
PLoS One; 2012; 7(10):e47469. PubMed ID: 23094052
[TBL] [Abstract][Full Text] [Related]
20. Update on urine-based markers for bladder cancer. How sensitive and specific are the new noninvasive tests?
Pirtskalaishvili G; Konety BR; Getzenberg RH
Postgrad Med; 1999 Nov; 106(6):85-6, 91-4. PubMed ID: 10576004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
